Infertility, Female study: Clomiphene Citrate
Official title Evaluation of a Long Versus Short Clomid Protocol for Controlled Ovarian Stimulation
ClinicalTrials.gov ID: NCT06701071
What this study is testing
What is Clomiphene Citrate?
An investigational oral medication being studied for ovarian stimulation in women with diminished ovarian reserve undergoing in‑vitro fertilization. It is designed to block estrogen receptors, which increases pituitary release of follicle‑stimulating hormone.
Also referred to as Clomid.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study wants to see if the long Clomid schedule can produce more mature eggs and lower costs and injections compared to the usual short schedule.
- Who it's for
- Women with diminished ovarian reserve who are planning to have in‑vitro fertilization.
- What's involved
- Participants will be randomly assigned to either the long Clomid protocol or the standard 5‑day Clomid plus GnRH antagonist protocol. They will take Clomid pills as directed and may have blood tests and ultrasound visits to monitor ovarian response.
- Time commitment
- The study lasts until the eggs are retrieved for IVF, with several clinic visits for medication, monitoring, and egg retrieval.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 44, women only
You may be able to join if
- Undergoing IVF
- Must meet POSEIDON criteria based on clinic evaluation
- Female partner: Antral follicle count of 2 or more and age \<45 at time of stimulation start
- Male partner/sperm source: Cannot be azoospermic
- Planning freeze-all cycle (regardless of blastocyst or cleavage stage culture) or fresh transfer if assigned by chance to short Clomid group
You likely can't join if
- Normal ovarian reserve or good response
- Allergy or adverse reaction to Clomid
- Minimal stimulation protocols
- History of prior premature ovulation
See the full eligibility criteria
- Undergoing IVF
- Must meet POSEIDON criteria based on clinic evaluation
- Female partner: Antral follicle count of 2 or more and age \<45 at time of stimulation start
- Male partner/sperm source: Cannot be azoospermic
- Planning freeze-all cycle (regardless of blastocyst or cleavage stage culture) or fresh transfer if assigned by chance to short Clomid group
- Planning 36-hour trigger window
- Normal ovarian reserve or good response
- Allergy or adverse reaction to Clomid
- Minimal stimulation protocols
- History of prior premature ovulation
The study team makes the final eligibility decision.
Where it is enrolling
- Pasadena, California, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 44 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Pasadena, California, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.